Podcasts - 24 Nov `25Topical Rapamycin — Vitiligo’s Next Big Hope? (Ep. 54)

Podcast

Topical Rapamycin — Vitiligo’s Next Big Hope? (Ep. 54)

From Easter Island soil to modern skin science — meet rapamycin, the molecule that might just change vitiligo care.

Once known mainly as an anti-rejection drug for organ transplants, rapamycin is now being tested as a topical treatment that could both calm the immune attack and help pigment return. Early studies look promising: minimal side effects, slow but steady repigmentation, and surprisingly good tolerance.

In this episode, we explore:

  • How rapamycin rewires the skin’s immune balance
  • Why it’s called both a suppressor and a rejuvenator
  • What Phase II trials are revealing so far
  • And whether this “longevity drug” might also restore color to the skin

It’s too early to call it a breakthrough — but this little molecule from a far-off island might just be the next quiet revolution in vitiligo therapy.

Prefer reading? Topical Rapamycin: Could This Be Vitiligo’s Next Big Breakthrough?

🎙️ Listen to Deep Dive in Vitiligo

You can listen to Deep Dive in Vitiligo on your favorite podcast platform:

🍎 Apple Podcasts
🟢 Spotify
📦 Amazon Music
❤️ iHeart Radio
🎧 Player FM
🎙️ Podchaser
🎤 Podbean

Pick your platform, hit subscribe, and we'll meet you there.



No cover image

FAQOther Questions

  • Isn't it just a cosmetic disorder?

    Contrary to popular belief, vitiligo is not merely a cosmetic issue but a complex autoimmune disorder that affects the body’s largest organ—along with other vital systems—and is...

  • Is it Bitiligo? Vitaligo? Veteligo?

    There are so many different ways that people try and spell or even pronounce Vitiligo. Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vitag...

  • Why Does the IRS Still Show an Old Revocation for VR Foundation?

    IRS Status · A Short FAQ The old entry records the past. Publication 78 shows where VR Foundation stands today. Updated August 2026 · EIN 45-2498489 Tax records are rarely elega...